Ortataxel
Clinical data
ATC code
  • none
Identifiers
  • (3aS,4R,7R,8aS,9S,10aR,12aS,13S,13aS)-7,12a-bis(acetyloxy)-4-({(2R,3S)-3-[tert-butoxycarbonyl)amino]-2-hydroxy-5-methylhexanoyl}oxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano[1,3]dioxolo[8,9]cyclodeca[1,2-d][1]benzoxet-13-yl benzoate
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard100.158.836 Edit this at Wikidata
Chemical and physical data
FormulaC44H57NO17
Molar mass871.930 g·mol−1
3D model (JSmol)
  • CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@]5(C2(C)C)[C@H]([C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)OC(=O)O5)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C
  • InChI=1S/C44H57NO17/c1-20(2)17-25(45-38(53)61-40(6,7)8)29(49)37(52)57-30-21(3)28-31(56-22(4)46)33(50)42(11)26(48)18-27-43(19-55-27,60-23(5)47)32(42)35(58-36(51)24-15-13-12-14-16-24)44(41(28,9)10)34(30)59-39(54)62-44/h12-16,20,25-27,29-32,34-35,48-49H,17-19H2,1-11H3,(H,45,53)/t25-,26-,27+,29+,30+,31+,32-,34-,35-,42+,43-,44+/m0/s1
  • Key:BWKDAMBGCPRVPI-ZQRPHVBESA-N
  (verify)

Ortataxel is a drug used in chemotherapy. As of June 2009, Spectrum Pharmaceuticals has the drug in a Phase 2 clinical trial.[1]

References

  1. ^ Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti G, Rulli E, D'Incalci M (May 2019). "Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma". Journal of Neuro-Oncology. 142 (3): 455–462. doi:10.1007/s11060-019-03116-z. PMID 30726533. S2CID 59606955.


Categories